Insider Trading Review: Daxor Corporation $DXR

stock-exchange-1376107_1920

Daxor Corporation (ARCA:DXR) insider have most recently took part in a trading activity. On Aug 25, 2017 Feldschuh Michael Richard, President & CEO bought 400 shares having total worth of $2,240 at the price of $5.6 per share, following the transaction a total of 172,997 shares owned by Feldschuh Michael Richard. Before this latest buy, Feldschuh Michael Richard purchased DXR at 2 other times during the past twelve months, for a total investment of $3,992 at an average of $7.61 per share.

The stock has experienced a total of 1 insider trades in the past three months. These trades include 1 buy trades. Furthermore, over the past 12 months , the stock was traded 4 times by insiders. In 1 of these trades, the insider was a seller while an employee of the company was the buyer in 3 instances.

Time Frame Number of Insider Buy Number of Insider Sell Stock Price Change(%)
3 Month 1 0 -19.57%
12 Month 3 1 -30.24%

Shares of Daxor Corporation (ARCA:DXR) traded down 0.88% on Aug 24, 2017, hitting $5.63. 8,513 shares of the company’s stock traded hands. Daxor Corporation has a 52 week low of $5.63 and a 52 week high of $9.48. The company’s market cap is $30 million.

Daxor Corporation was originally incorporated in New York State as Iatric Corporation in May 1971for cryobanking services and continues these services through its wholly-owned subsidiary, Scientific Medical Systems. In October 1971, the name Iatric Corporation was changed to Idant Corporation. In May 1973, the name Idant Corporation was changed to Daxor Corporation. It is a medical device manufacturing Company, which offers additional biotech services, such as cryobanking, through its wholly owned subsidiary Scientific Medical Systems Corp. The main focus of the Company has been the development and marketing of an instrument that rapidly and accurately measures human blood volume. This instrument is used in conjunction with a single use diagnostic injection and collection kit that the Company also sells to its customers. The Company’s main focus has been on the development of the BVA-100(r) Blood Volume Analyzer, an instrument that rapidly and accurately measures human blood volume. The instrument is used in conjunction with Volumex(r), a single-use radiopharmaceutical diagnostic injection and collection kit. The BVA-100 has also been used to aid in the diagnosis and treatment of polycythemia, hypertension, anemia, chronic fatigue, and to aid in presurgical evaluation. Additional possible uses include management of kidney dialysis, ultrafiltration, and blood optimization for elective surgery. The Company’s marketing of the blood volume analyzer could be divided roughly into three phases: initial beta testing at local facilities, late-stage beta testing at nationally recognized institutions – with an emphasis on developing studies for publication, and marketing of the instrument for clinical use. During late-stage beta testing and the marketing phase, the instrument continued to experience a number of major technical improvements and alternations. It competes for customers based on a variety of factors, including reputation, customer service, performance, expertise, price and scope of service offerings.

William White

William White is a financial writer. He graduated with a degree in Economics. He has contributed to major financial websites and print publications for over 8 years. He handles much of this site's news coverage for corporate insider activity, and occasionally cover other areas of financial sector.

Latest posts by William White (see all)

About the Author

William White
William White is a financial writer. He graduated with a degree in Economics. He has contributed to major financial websites and print publications for over 8 years. He handles much of this site's news coverage for corporate insider activity, and occasionally cover other areas of financial sector.